[2-Methoxy-2-(1-methoxybutan-2-yloxy)ethyl] (4-nitrophenyl) carbonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-Methoxy-2-(1-methoxybutan-2-yloxy)ethyl] (4-nitrophenyl) carbonate
• 英文别名: [2-methoxy-2-(1-methoxybutan-2-yloxy)ethyl] (4-nitrophenyl) carbonate
• 化学式: C15H21NO8
• 分子量: 343.33
• InChiKey: BWZJCZLGCULLPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF<br/>[FR] COMPOSÉS DE TUBULYSINE ET LEURS CONJUGUÉS
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014160360A1

  公开（公告）日：2014-10-02

  A tubulysin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a tubulysin compound having a molecular weight < 5 kDa. LD and Lp are distinct linkers connecting the tubulysin compound and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-tubulysin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种管状霉素化合物结合物。该结合物包括基于蛋白质的识别分子（PBRM）和与一个或多个-LD-D取代的聚合物载体，其中基于蛋白质的识别分子通过Lp连接到聚合物载体上。每个D的出现独立地是具有分子量<5 kDa的管状霉素化合物。LD和Lp是连接管状霉素化合物和PBRM到聚合物载体的不同连接物。还公开了用于与PBRM结合形成本文所述聚合物-管状霉素化合物-PBRM结合物的聚合物支架，包括结合物的组合物，其制备方法，以及使用结合物或其组合物治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：EP2717916B1

  公开（公告）日：2017-03-08
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS PROTÉINE-POLYMÈRE-MÉDICAMENT
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093394A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer- drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.